Kahua ʻenehana Hybridoma
Hāʻawi ʻo Alpha Lifetech i nā mea kūʻai aku me ka antibody i hōʻoia ʻia i ka maikaʻi a me nā huahana a me nā lawelawe antibody recombinant.
Noi i ka ʻōlelo kūʻai01
Kahua ʻenehana Hybridoma
He nui ka ʻike o Alpha Lifetech ma ke kahua o ka hoʻomohala ʻana i ka antibody. I nā makahiki i hala iho nei, ua hoʻokumu ʻo Alpha Lifetech i kahi kahua hoʻomohala antibody piha (me ka hoʻomohala ʻana i ka antibody monoclonal, ka hoʻomohala ʻana i ka antibody polyclonal, ka hoʻomohala ʻana i ka antibody monoclonal recombinant, a me nā lawelawe hoʻomākaukau a me ka hoʻomohala ʻana i ka antibody).
Hāʻawi ʻo Alpha Lifetech i nā mea kūʻai aku me nā huahana a me nā lawelawe antibody i hōʻoia ʻia i ka maikaʻi a me nā huahana antibody recombinant, a he ikaika ka kikoʻī o nā antibodies i hoʻomākaukau ʻia a me ke kūpaʻa maikaʻi. Hiki ke hoʻohana ʻia nā mea hana a me nā lako hoʻomaʻemaʻe antibody he nui e hāʻawi i nā lawelawe hoʻomaʻemaʻe antibody mai nā kumu like ʻole e like me ka lāpaki, hipa, moa, nā antibodies monoclonal ʻiole, a me nā lawelawe hoʻomaʻemaʻe protein A/G affinity a me nā lawelawe hoʻokaʻawale antibody.
Ma muli o nā ʻano hana hoʻomākaukau antibody like ʻole e like me ka ʻenehana cell hybridoma, hiki iā Alpha Lifetech ke hāʻawi i nā lawelawe i hoʻopilikino ʻia no nā antibodies monoclonal a me polyclonal o nā ʻano like ʻole. Eia kekahi, hiki ke hāʻawi ʻia kahi ʻano lawelawe mai ka hoʻonohonoho ʻana o ka throughput kiʻekiʻe, ka hoʻomākaukau ʻana o ka antibody, ka hoʻomaʻemaʻe antibody a hiki i ka hōʻoia antibody. E koho mākou i ke ʻano hoʻomaʻemaʻe e pili ana i ke kumu kikoʻī o ka mea kūʻai aku. Ma muli o nā ʻōnaehana kahua piha e like me ka paepae hoʻomohala antibody a me ka paepae protein, uhi ʻo Alpha Lifetech i nā lawelawe upstream a me downstream o ka hana antibody, e hāʻawi ana i ka hoʻomaʻemaʻe antibody, ka hoʻonohonoho ʻana o ka throughput kiʻekiʻe antibody, ka hōʻoia antibody a me nā lawelawe loea ʻē aʻe.
ʻenehana Hybridoma
Hiki ke hoʻohana ʻia ka ʻenehana Hybridoma e hoʻomākaukau i nā antibodies monoclonal. Ma ka hoʻohui ʻana i nā cell spleen mai nā ʻiole i hoʻopili ʻia me nā cell myeloma mai nā kānaka a i ʻole nā ʻiole, hoʻokumu ʻia nā cell hybridoma a hūnā i nā antibodies kikoʻī. Hiki ke hoʻohana ʻia nā antibodies monoclonal i loaʻa i ka ʻiole i hana ʻia i ka noiʻi ʻepekema e like me ka enzyme-linked immunosorbent assay, radioimmunoassay, immunohistochemistry, flow cytometry, protein purification, etc. ʻO nā laʻana antibody monoclonal e komo pū me ka ascites, hybridoma supernatant, etc. ʻO ka laʻana i loaʻa ma ka hoʻokomo ʻana i nā cell hybridoma i loko o ka lua ʻōpū o nā holoholona a me ka hoʻohana ʻana i ke kaiapuni physiological o ka lua ʻōpū o ka holoholona e hana i nā antibodies ua kapa ʻia ʻo ascites sample. Hiki i nā cell Hybridoma i hoʻokomo ʻia i loko o ka lua ʻōpū o nā holoholona ke hoʻonui a hūnā i nā antibodies monoclonal, hiki ke hōʻiliʻili i loko o nā ascites. Ma muli o ka hiki ke loaʻa nā haumia (nā protein holoholona, nā hormones, etc.) i loko o kēia mau antibodies, pono ka hoʻomaʻemaʻe. Ma muli o ka hana huna o nā lymphocytes B, hoʻokuʻu pinepine ʻia nā antibodies monoclonal i loko o ka medium moʻomeheu i ka wā e mahi ai i nā cell hybridoma. ʻO ka wai e loaʻa ana nā antibodies monoclonal i loko o ka medium moʻomeheu ua kapa ʻia ʻo hybridoma supernatant. He kiʻekiʻe iki ka maʻemaʻe o nā antibodies monoclonal i loko o ka supernatant, akā pono ka hoʻomaʻemaʻe hou aʻe no ka hoʻomākaukau nui ʻana i ka wā e loaʻa ai lākou ma o ka moʻomeheu in vitro.
Hiki i ka hoʻomaʻemaʻe ʻana i ka antibody ke hoʻokaʻawale i nā antibodies maʻemaʻe kiʻekiʻe mai nā hui. I kēia manawa, ʻo ka hoʻomaʻemaʻe ʻana i ka antibody affinity a me ka hoʻokaʻawale ʻana a me ka hoʻomaʻemaʻe ʻana i ka antibody nā ʻano hana hoʻomaʻemaʻe antibody i hoʻohana pinepine ʻia, ʻo ia hoʻi ka hoʻomaʻemaʻe ʻana i ka protein A/G, ka chromatography hoʻololi ion, ka filtration gel, ka precipitation a me ka chromatography interaction hydrophobic. I waena o lākou, ua kaulana loa ka lawelawe hoʻomaʻemaʻe ʻana i ka protein A/G affinity i nā noi hoʻomaʻemaʻe antibody like ʻole. Hōʻike ʻia ke kaʻina hana o Alpha Lifetech e hoʻomākaukau ana i nā antibodies monoclonal e pili ana i ka ʻenehana hybridoma ma ke Kiʻi 1.
Kiʻi 1 Kiʻikuhi hana no ka hoʻomākaukau ʻana i nā antibodies monoclonal e pili ana i ka ʻenehana hybridoma.
ʻO ka ʻenehana hui lāʻau antibody a me ka Hybridoma
ʻO ka antibody drug conjugate (ADC) kahi mea olaola hou e hoʻopili kemika i nā antibodies me nā lāʻau cytotoxic. Hoʻohui ka antibody drug conjugate i ka hiki ke ʻike kikoʻī o nā antibodies me ka hopena pepehi ikaika o nā lāʻau cytotoxic, a hāʻawi pololei i nā lāʻau cytotoxic i loko o nā cell tumor ma o nā antibodies, a laila e hoʻokō ai i ka mālama pololei. Hoʻomākaukau pinepine ʻia ka ʻāpana antibody i nā lāʻau ADC ma o ka ʻenehana hybridoma a i ʻole nā ʻano hana hana antibody ʻē aʻe, e like me ka ʻenehana antibody genetic engineering. Hāʻawi ka ʻenehana Hybridoma i nā mea maka antibody kiʻekiʻe no nā lāʻau ADC. He kuleana koʻikoʻi nā lāʻau ADC a me nā antibodies monoclonal i hoʻomākaukau ʻia ma o ka ʻenehana hybridoma i nā kahua e like me ka mālama ʻana i ka maʻi kanesa. Hiki ke hoʻohana wale ʻia a i ʻole i ka hui pū ʻana e hoʻonui i ka pono therapeutic.
Loaʻa i nā antibodies monoclonal i hoʻomākaukau ʻia e ka ʻenehana hybridoma ke kikoʻī kiʻekiʻe, hiki ke hoʻopaʻa pololei a ʻike i nā antigens kikoʻī, a hiki ke hana ʻia ma kahi pae nui. Ma o ka ʻenehana hoʻonohonoho hybridoma, hiki ke unuhi ʻia a hoʻonohonoho ʻia nā genes antibody i loko o nā cell hybridoma e loaʻa nā kaʻina like, he mea maikaʻi ia no ka hōʻike ʻana o ka antibody ma hope. Hiki ke hoʻohana ʻia nā antibodies monoclonal i hoʻomākaukau ʻia ma o ka ʻenehana hybridoma e ʻike i nā māka maʻi kikoʻī, e like me nā māka tumor, nā antigens viral, a pēlā aku, e hāʻawi ana i ke kākoʻo ikaika no ka ʻike mua ʻana i nā maʻi. Eia kekahi, hiki ke hoʻohana ʻia i nā hoʻokolohua e like me ka immunoblotting a me ka immunohistochemistry e aʻo i ka hōʻike ʻana o ka protein, localization, structure, a me ka hana.
ʻenehana hybridoma Hana Hana Antibody Hana Hana Hana
| Nā ʻanuʻu | ʻIke lawelawe | Ka Papa Manawa |
|---|---|---|
| KaʻAnuʻu Hana 1: Ka pale ʻana i nā holoholona | (1) Hoʻopili ʻia nā holoholona i 4 mau manawa, hoʻopili ʻia nā holoholona i 1 mahele lāʻau, he 5 mau mahele lāʻau i hoʻopili ʻia. (2) ʻAʻole maikaʻi ka serum ma mua o ka hōʻiliʻili ʻia ʻana o ka immunization, a ua hana ʻia ʻo ELISA ma ka hā o ka mahele e ʻike ai i ka serum titer. (3) Inā kūlike ka titer antibody serum o ka hā o ka mahele i nā koi, e lawelawe ʻia hoʻokahi mahele hou o ka immunization i 7 mau lā ma mua o ka hōʻiliʻili koko. Inā ʻaʻole ia e kūlike i nā koi, e hoʻomau ʻia ka immunization maʻamau. (4) Mana kūpono, ua hoʻokaʻawale ʻia nā pūnaewele Spleen no ka hoʻohui ʻana o nā pūnaewele. | 10-12 pule |
| KaʻAnuʻu Hana 2: Fusion a me ka Nānā ʻana | (1) Hoʻohuihui: Ma hope o ka pale ʻana, ua hōʻiliʻili ʻia nā pūnaewele spleen ʻiole a ua hoʻohui ʻia me nā pūnaewele myeloma. (2) Hoʻonui a me ka nānā ʻana: Ua hoʻokomo ʻia nā pūnaewele hybridoma i loaʻa i ka hoʻonui a me ka nānā ʻana o ELISA e loaʻa ai nā clones kūpono loa. | 6 pule |
| KaʻAnuʻu Hana 3: Subclone | Ke hoʻopili nei i nā pūnaewele makuahine maikaʻi 15-25 me ka hoʻohana ʻana i ke ʻano dilution palena, a me ka hoʻoholo hope ʻana i nā clones maikaʻi 10-15 | 3-4 pule |
| KaʻAnuʻu Hana 4: Ka Hana ʻana o Ascites a me ka Hoʻomaʻemaʻe ʻana o ka Antibody | (1) Ka hana ʻana o nā ascites: Hoʻohana ʻia nā ʻano hybridoma 10-15 no ka hana ʻana o nā ascites i nā ʻiole (inā loaʻa ka nui o nā ʻano hybridoma, e hoʻouna ʻia lākou ma ke ʻano cellular) (2) Ka ʻike ʻana i ka Ascites: ʻIke ʻana o ka Ascites ELISA, ka ikaika (protein/virus>10 ^ 5, mole liʻiliʻi/peptide>10 ^ 4) no ka hoʻomaʻemaʻe ʻana ma hope (3) Hoʻomaʻemaʻe ʻana o ka Protein A/G: Hoʻomaʻemaʻe ʻana o nā Ascites | 3-4 pule |
| KaʻAnuʻu Hana 5: Hoʻouna ʻana | (1) E hoʻolako i 3-5 mau ʻano monoclonal antibody hybridoma. (2) Hāʻawi kēlā me kēia cell hybridoma i 1mg o ka antibody i hoʻomaʻemaʻe ʻia (ascites purification). (3) Hōʻike Hana Hoʻokolohua | 1 pule |
Nā ʻano like ʻole
Hiki ke hāʻawi ʻia ka palekana i nā holoholona like ʻole, me ka palena ʻole i nā ʻiole, nā lāpaki, nā hipa, a pēlā aku
Pahuhopu he nui
Ma muli o ka ʻenehana hybridoma, loaʻa nā lawelawe ʻike antibody pahuhopu he nui: nā protein, peptides, nā mole liʻiliʻi, nā virus, nā protein membrane, mRNA, a pēlā aku.
Nā Moʻolelo Hiki ke Hahai ʻia
Nā kūlana hoʻomalu maikaʻi QC (ka ikaika o ka pale ʻana, ka hoʻomalu maikaʻi PBMC, ka hoʻomalu maikaʻi o ka waihona puke, a me ka hoʻomalu maikaʻi hōʻoia screening), nā hōʻike hoʻokolohua Pelekania, nā moʻolelo hoʻokolohua mua
Polokalamu Pilikino
Hoʻopilikino ʻia ka papahana pilikino hoʻokahi ma hoʻokahi e hoʻokō i nā pono papahana noiʻi o nā mea kūʻai aku like ʻole
Ka lawelawe hoʻomohala ʻana i ka lāʻau lapaʻau Monoclonal
Hiki iā mākou ke hāʻawi i nā lawelawe hoʻomohala antibody monoclonal kiʻekiʻe, maʻemaʻe kiʻekiʻe, a me ke kikoʻī loa, me ka hana ʻana o nā antibodies monoclonal mouse a me nā antibodies monoclonal rabbit.
Kahua ʻenehana Hybridoma
Me ka papahana immunization, nā lawelawe hoʻomākaukau antibody, ka hoʻomaʻemaʻe antibody, ka antibody high throughput sequencing, ka antibody validation, a pēlā aku
Kahua Hoʻokaʻawale Kelepona B Hoʻokahi
Loaʻa iā Alpha Lifetech nā pono i ka manawa nānā a me ka loaʻa ʻana o nā antibodies kiʻekiʻe. Hiki iā ia ke hāʻawi i ka hoʻolālā antigen, synthesis, a me ka hoʻololi ʻana, ka palekana holoholona, ka nānā ʻana i ka hoʻonui ʻana o nā cell B hoʻokahi, ka hoʻonohonoho ʻana o nā cell hoʻokahi.
Kahua Hoʻomohala Antibody Hōʻike Phage
Hiki iā Alpha Lifetech ke hāʻawi i nā lawelawe loea no ka hoʻomohala ʻana i ka antibody hōʻike phage mai ka hoʻomākaukau ʻana i ka antibody, ka hoʻomaʻemaʻe ʻana i ka antibody, ka hoʻonohonoho ʻana i ka antibody, a pēlā aku.
Kumuwaiwai ʻenehana pili
Hoʻolauna i ka ʻenehana HybridomaWIDEO
Inā he mau nīnau kāu, e ʻoluʻolu e hoʻokaʻaʻike mai iā mākou i kēlā me kēia manawa.
Leave Your Message
2018-07-16 
0102